FDA supports tighter restrictions on hydrocodone
WASHINGTON — The Food and Drug Administration is recommending tighter restrictions on prescription medicines containing hydrocodone, the highly addictive painkiller that has grown into the most widely prescribed drug in the United States.
In a major policy shift, the agency said in an online notice on Thursday that hydrocodone-containing drugs should be subject to the same restrictions as other narcotic drugs such as oxycodone and morphine.
More than a decade has passed since the Drug Enforcement Agency asked the FDA to reclassify hydrocodone so that it would be subject to the same restrictions as other opioid drugs. The FDA did not issue a formal announcement about its decision, which has long been sought by many patient advocates, doctors and lawmakers.
In early December, the FDA says it will formally request that hydrocodone be classified as a Schedule II drug, limiting who can write a prescription and how many times it can be refilled.
Show commenting policy
TribLive commenting policy
- NYC’s High Line completed, culminating 15-year effort
- White House breach ‘a cry out for help,’ alleged intruder’s ex-wife says
- Officials say too many in the 18-64 age range skip flu vaccination
- March around the world seek to put focus on climate change
- U.S. confident it’ll have allies for airstrikes against ISIS
- Legislators urge Secret Service to reassess White House security
- Beads in beauty products called toxin
- Mentally ill Pa. man might go free in 9/11 scare
- 32 structures destroyed in California’s King wildfire
- Backers seek expansion of Till civil rights death law
- Man seen with UVa student faces driving charge